News stories about Opko Health (NASDAQ:OPK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Opko Health earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.7372106853068 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
Opko Health (NASDAQ:OPK) traded up $0.17 on Friday, reaching $5.25. 3,912,221 shares of the company’s stock traded hands, compared to its average volume of 4,515,847. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Opko Health has a 1-year low of $4.50 and a 1-year high of $12.15.
Opko Health (NASDAQ:OPK) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million for the quarter, compared to the consensus estimate of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. Opko Health’s revenue was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.03) EPS. analysts expect that Opko Health will post -0.27 EPS for the current year.
OPK has been the subject of several research reports. BidaskClub lowered shares of Opko Health from a “hold” rating to a “sell” rating in a report on Saturday, November 11th. Cantor Fitzgerald initiated coverage on shares of Opko Health in a research report on Thursday, August 17th. They issued an “overweight” rating and a $20.00 target price on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $6.50 target price (down from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $16.00 target price on shares of Opko Health in a research report on Monday, September 25th. Finally, Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Opko Health currently has a consensus rating of “Hold” and an average price target of $13.97.
In related news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction on Monday, October 30th. The stock was acquired at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the acquisition, the insider now directly owns 6,678,752 shares in the company, valued at approximately $20,370,193.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Phillip Md Et Al Frost acquired 80,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were bought at an average cost of $6.01 per share, with a total value of $480,800.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at $18,444,395.51. The disclosure for this purchase can be found here. Insiders bought a total of 1,052,238 shares of company stock worth $4,374,796 in the last quarter. Company insiders own 40.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/09/opko-health-opk-getting-somewhat-favorable-news-coverage-analysis-shows.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.